MedTrace Logo

Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）

NCT05281549 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2022-03-31

No results posted yet for this study

Summary

The trial is prospective, block randomized, open-label, blinded endpoint (PROBE) design. Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be randomized 1:1:1 to 0.25mg/kg or 0.40mg/kg intravenous tenecteplase or 0.9 mg/kg alteplase before all participants undergo endovascular thrombectomy.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Alteplase

Alteplase 0.9mg/kg are being used.

DRUG

Tenecteplase

Tenecteplase 0.25mg/kg are being used.

DRUG

Tenecteplase

Tenecteplase 0.4mg/kg are being used.

Sponsors & Collaborators

  • Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd

    collaborator UNKNOWN

  • The Place Pharmaceutical(Jiangsu) Co., Ltd

    collaborator UNKNOWN

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Shuya Li · IRB of Beijing Tiantan Hospital,Capital Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-02
Primary Completion
2022-01-28
Completion
2022-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05281549 on ClinicalTrials.gov